Nautilus Biotechnology(US:NAUT) Globenewswire·2026-01-28 13:00Core Insights - Nautilus Biotechnology, Inc. is collaborating with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation for Parkinson's Research to study the alpha-synuclein protein's role in Parkinson's disease, supported by a $1.6 million grant [1][2][5] Research Collaboration - The collaboration aims to explore the connection between alpha-synuclein and Parkinson's disease, focusing on the protein's various forms and modifications to enhance understanding of disease biology [2][3] - The project combines expertise in neurodegeneration and advanced proteomics technology to develop a single-molecule assay for measuring alpha-synuclein proteoforms [3][4][7] Technological Advancements - Nautilus is utilizing its novel single-molecule platform and Iterative Mapping method to uncover biological insights related to alpha-synuclein and tau proteins [4][7] - The collaboration is expected to lead to innovative assays that will enable precise mapping of post-translational modifications of alpha-synuclein, which could improve diagnostics and therapeutic strategies for Parkinson's disease [6][7] Institutional Expertise - Weill Cornell Medicine-Qatar brings significant expertise in chemical biology and neurology, which will support the development of proteoform standards and affinity reagents for the research [5][9] - The lab of Hilal A. Lashuel at WCM-Q is recognized for its extensive research on alpha-synuclein and its post-translational modifications, contributing to the foundation of the proteoform assay [5][6]